Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082
Milestone validates the clinical potential of BSI-082 as a synergistic combination partner for antibody-drug conjugates (ADCs). NEWARK, DE, UNITED STATES, February 3, 2026 /EINPresswire.com/ -- Biosion, Inc. (“Biosion”), a global, clinical-stage …